These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 17291993

  • 1. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
    Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, Antonini TM, Antonini R, Diczfalusy U, Iuliano L.
    Free Radic Biol Med; 2007 Mar 01; 42(5):698-705. PubMed ID: 17291993
    [Abstract] [Full Text] [Related]

  • 2. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 01; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 3. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
    Arca M, Cambuli VM, Montali A, Sentinelli F, Filippi E, Campagna F, Quagliarini F, Antonini R, Romeo S, Baroni MG.
    Nutr Metab Cardiovasc Dis; 2009 Nov 01; 19(9):660-6. PubMed ID: 19632099
    [Abstract] [Full Text] [Related]

  • 4. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 01; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 5. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 01; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 6. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 01; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 7. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
    Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF.
    J Intern Med; 2005 May 01; 257(5):438-45. PubMed ID: 15836660
    [Abstract] [Full Text] [Related]

  • 8. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
    Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Mar 01; 57(3):380-6. PubMed ID: 18249211
    [Abstract] [Full Text] [Related]

  • 9. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 01; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 10. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
    Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, Manzato E, Bittolo Bon G, Fellin R.
    Nutr Metab Cardiovasc Dis; 2005 Feb 01; 15(1):47-55. PubMed ID: 15871851
    [Abstract] [Full Text] [Related]

  • 11. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
    Blanco-Colio LM, Martín-Ventura JL, Sol JM, Díaz C, Hernández G, Egido J.
    J Am Coll Cardiol; 2004 Apr 07; 43(7):1188-94. PubMed ID: 15063428
    [Abstract] [Full Text] [Related]

  • 12. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep 07; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 13. In vivo interconversion of 7beta-hydroxycholesterol and 7-ketocholesterol, potential surrogate markers for oxidative stress.
    Larsson H, Böttiger Y, Iuliano L, Diczfalusy U.
    Free Radic Biol Med; 2007 Sep 01; 43(5):695-701. PubMed ID: 17664133
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.
    Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129
    [Abstract] [Full Text] [Related]

  • 15. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R, Sobra J, Kvasnicka J, Procházková R, Kvasilová M, Haas T.
    Cas Lek Cesk; 1996 Jul 26; 135(13):413-6. PubMed ID: 8925538
    [Abstract] [Full Text] [Related]

  • 16. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C, Lilli S, Gentile A, Patti L, Di Marino L, Cipriano P, Riccardi G, Rivellese AA.
    Eur J Clin Invest; 2006 Aug 26; 36(8):560-5. PubMed ID: 16893378
    [Abstract] [Full Text] [Related]

  • 17. Baseline oxysterols and other markers of oxidative stress, inflammation and malnutrition in the vitamin e and intima media thickness progression in end-stage renal disease (VIPER) cohort.
    Boaz M, Iuliano L, Himmelfarb J, Matas Z, Micheletta F, McMonagle E, Friedman V, Natoli S, Gvirtz G, Biro A, Smetana S, Sabo G, Gafter U, Weinstein T.
    Nephron Clin Pract; 2005 Aug 26; 100(4):c111-9. PubMed ID: 15849477
    [Abstract] [Full Text] [Related]

  • 18. High preoperative recipient plasma 7beta-hydroxycholesterol is associated with initial poor graft function after liver transplantation.
    Corradini SG, Micheletta F, Natoli S, Iappelli M, Di Angelantonio E, De Marco R, Elisei W, Siciliano M, Rossi M, Berloco P, Attili AF, Diczfalusy U, Iuliano L.
    Liver Transpl; 2005 Dec 26; 11(12):1494-504. PubMed ID: 16258953
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
    Chatley P, Badyal DK, Calton R, Khosla PP.
    Methods Find Exp Clin Pharmacol; 2007 Apr 26; 29(3):217-21. PubMed ID: 17520105
    [Abstract] [Full Text] [Related]

  • 20. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
    Yesilbursa D, Serdar A, Saltan Y, Serdar Z, Heper Y, Guclu S, Cordan J.
    Kardiol Pol; 2005 Jun 26; 62(6):526-30. PubMed ID: 16123850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.